Peer-influenced content. Sources you trust. No registration required. This is HCN.
Clinical Advances in Hematology & Oncology
The differences between bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapy, the side effects of bispecific antibodies, how the antibodies may address unmet needs in lymphoma, and a few other observations are discussed in this interview with Dr. John N. Allan, Assistant Professor of Medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medicine in New York.
Hematology/Oncology August 22nd 2022
Talking about the limitations of the International Workshop on CLL (iwCLL) response criteria for chronic lymphocytic leukemia (CLL) in the era of novel medications is Dr. Alexey V. Danilov, Professor and Co-Director of the Toni Stephenson Lymphoma Center at the City of Hope National Medical Center in Duarte, California.
The Journal of Clinical Investigation (JCI)
Reversal of HLA-I loss is crucial for an effective antitumor cytotoxic T cell response. Thus, HLA-I–upregulating drugs could augment immunotherapy response. The authors describe here a small-molecule USP7 inhibitor as a promising avenue for pharmacologic upregulation of HLA-I in MCC.
Oncology, Medical August 22nd 2022
Cancer Therapy Advisor
The meta-analysis included data from nearly 13,000 patients across 30 published trials. Grade 3 or 4 AEs occurred in nearly 70% of patents receiving TKIs compared with 37% for those receiving ICIs.
Oncology, Medical August 16th 2022
Clinical Oncology News
When immune checkpoint inhibitor therapy was started, detectable levels of acetaminophen in the plasma were linked to significantly poorer PFS and OS. The fact that poorer clinical outcomes were demonstrated to be unrelated to other prognostic variables, such as age, performance status, the quantity of past lines of therapy, and tumor kind, is noteworthy.
Oncology, Medical August 15th 2022
OBR Oncology
Results from the phase 1b CodeBreak 100/1 trial show that administering the novel KRASinhibitor sotorasib alone prior to combining it with an immune checkpoint inhibitor led tolower rates of grade 3-4 treatment-related adverse events compared with beginningadministration of the treatments concurrently.